RxDoctor Payments Data

Amit Gupta, MD

Interventional Cardiology · Easton, PANPI 1265640148

Payments from drug & device makers

$58,894in general payments, 2019–2025

Across 35 payments — averaging $1682.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma Global Development$57K
  • Edwards Lifesciences$310
  • Medicure Pharma Inc.$300
  • Biotronik Inc.$145
  • Heartflow, Inc.$138
  • Abiomed$132
  • plus $612 from 11 others

What the payments were for

  • Consulting fees$30018%
  • Food & beverage$1,23075%
  • Education$1077%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,894 in reported general payments places this provider in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$140,580
Medicare patients
1,534
Services billed
3,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$213,880
XareltoRivaroxaban36$32,210
EntrestoSacubitril/Valsartan19$29,094
JardianceEmpagliflozin21$12,662
BrilintaTicagrelor22$9,700
Metoprolol Succinate379$5,820
Ranolazine ErRanolazine34$2,863
Atorvastatin Calcium163$1,960
Rosuvastatin Calcium148$1,732
Ezetimibe75$1,483
Amiodarone Hcl19$1,376
Isosorbide Mononitrate ErIsosorbide Mononitrate97$1,169
Potassium Chloride58$1,118
Flecainide Acetate12$975
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123$213,880290 claims
Johnson & JohnsonXarelto$17$32,21036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →